ERP-Based Research on the Modulation of Remimazolam on Working Memory and Brain Network Mechanisms in Glioma Patients

Inclusion Criteria: A. Healthy brain group: * Aged 18-65 years; * Native speakers of Chinese; * Right-handed; ④ Normal vision or corrected vision; ⑤ Healthy brain patient population scheduled for non-neurosurgical operations and anesthesia B. Glioma brain group * Aged 18-65 years old; * Native speakers of Chinese; * Right-handed; ④ ASA physical status I-II; * Normal vision or corrected vision; * Patients with supratentorial glioma who have primary unilateral space-occupying lesions confirmed by CT/MRI and require surgery and anesthesia. Exclusion Criteria: A. Healthy brain group: * Allergic to remimazolam or with contraindications to remimazolam (myasthenia gravis, schizophrenia, severe depressive state); * History of drug abuse or alcoholism; * History of mental or neurological diseases that prevent cooperation in completing the trial; ④ Pregnant or lactating women; * Score of mini-mental state examination (MMSE) \< 27; ⑥ Past history of intracranial diseases or intracranial surgery B. Glioma brain group: * Receiving sedative treatment within 72 hours prior to the study; * Destruction of cerebral structural integrity such as open head injury or cerebral parenchyma resection; * Preoperative elevated intracranial pressure requiring mannitol or other intracranial pressure-lowering treatments, or preoperative radiotherapy and chemotherapy; * History of drug abuse or alcoholism; * Pregnant or lactating women; ⑥ Mini-Mental State Examination (MMSE) score \< 27; ⑦ History of allergic reaction to remimazolam or having contraindications to remimazolam. Remimazolam is a national controlled drug with addictive properties and must be used under the guidance of a doctor; ⑧ Those with other mental or neurological diseases who are unable to cooperate in completing the trial; ⑨ Unsuitable for participating in this study due to other reasons.